Current Press Releases
Endocrine Society encouraged by Lilly’s new lower-priced insulin
May 22, 2019
|Contact: Jenni Glenn Gingery
Associate Director, Communications and Media Relations
|Contact: Colleen Williams
Manager, Public Relations
Washington, DC - Eli Lilly and Company recently announced its authorized generic version of lispro is now available at a 50 percent lower list price than the brand name version, Humalog U-100. The Society is pleased at this step toward improving access to affordable insulin. According to a press release from the company, the generic lispro can now be ordered in pharmacies. This announcement is welcome news for patients who are currently paying out of pocket for Humalog U-100. According to Lilly, some insurers will be including generic lispro on their formularies.
For patients who wish to change to the generic version of lispro, prescribers should write for lispro insulin, rather than Humalog. Patients with questions about generic lispro and insulin affordability can contact the Lilly Diabetes Solution Center at (833) 808-1234.
The Endocrine Society continues to urge policymakers, drug manufacturers, insurance companies and pharmacy benefit managers to work together to stop the spiraling cost of insulin and other medications that has led to an ever-growing patchwork of complex, confusing, and difficult to access safety net programs.
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.